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Axolotls (urodele amphibians) have the unique ability, among vertebrates, to perfectly regenerate many parts of their body
including limbs, tail, jaw and spinal cord following injury or amputation. The axolotl limb is the most widely used structure as
an experimental model to study tissue regeneration. The process is well characterized, requiring multiple cellular and
molecular mechanisms. The preparation phase represents the first part of the regeneration process which includes wound
healing, cellular migration, dedifferentiation and proliferation. The redevelopment phase represents the second part when
dedifferentiated cells stop proliferating and redifferentiate to give rise to all missing structures. In the axolotl, when a limb is
amputated, the missing or wounded part is regenerated perfectly without scar formation between the stump and the
regenerated structure. Multiple authors have recently highlighted the similarities between the early phases of mammalian
wound healing and urodele limb regeneration. In mammals, one very important family of growth factors implicated in the
control of almost all aspects of wound healing is the transforming growth factor-beta family (TGF-b). In the present study, the
full length sequence of the axolotl TGF-b1 cDNA was isolated. The spatio-temporal expression pattern of TGF-b1i n
regenerating limbs shows that this gene is up-regulated during the preparation phase of regeneration. Our results also
demonstrate the presence of multiple components of the TGF-b signaling machinery in axolotl cells. By using a specific
pharmacological inhibitor of TGF-b type I receptor, SB-431542, we show that TGF-b signaling is required for axolotl limb
regeneration. Treatment of regenerating limbs with SB-431542 reveals that cellular proliferation during limb regeneration as
well as the expression of genes directly dependent on TGF-b signaling are down-regulated. These data directly implicate TGF-
b signaling in the initiation and control of the regeneration process in axolotls.
Citation: Le ´vesque M, Gatien S, Finnson K, Desmeules S, Villiard E ´, et al (2007) Transforming Growth Factor: b Signaling Is Essential for Limb
Regeneration in Axolotls. PLoS ONE 2(11): e1227. doi:10.1371/journal.pone.0001227
INTRODUCTION
Urodele amphibians, such as the axolotl (Ambystoma mexicanum),
have the unique ability, among vertebrates, to perfectly regenerate
many parts of their body throughout their life. Among the
complex structures that can be regenerated in the axolotl, the limb
is the most widely studied [1–3]. Limb regeneration represents an
elaborate process in which wound healing, cellular dedifferentia-
tion, tissue remodeling and patterning occur to replace the
amputated appendage. Understanding urodele limb regeneration
could be helpful in the design and development of novel therapies
in regenerative medicine. It is therefore interesting to highlight the
fact that following limb amputation, the axolotl will regenerate its
limb without any residual scar between the stump and the
regenerated structure [1,2]. The vast majority of adult vertebrates
including mammals, birds, fishes, anuran amphibians and reptiles
are incapable of regenerating complex structures such as limbs or
tail. In those species, wound healing results in scarring. Thus,
scarring, or fibrosis, seems to be a universal response to wounding
that spans the 3 layers (epidermis, dermis and hypodermis) of the
skin in vertebrates. The similarities between regeneration and
wound healing have been discussed by many authors [2,4–6] and
it has become apparent that a proper understanding of both
similarities and differences is essential to help us better
comprehend how regeneration is achieved in urodeles but not in
mammals.
Axolotl limb regeneration is considered by many to be divided
in two main phases [2,7,8]. The first phase is referred to as the
preparation phase and begins immediately following amputation
with the formation of a wound epithelium (WE) over the
amputation plane. Cellular dedifferentiation and migration, which
will eventually lead to the formation of a regeneration blastema,
also take place in this phase. In the second phase of limb
regeneration, referred to as the redevelopment phase, blastema
cells stop proliferating and start to redifferentiate to regenerate the
lost part [1,8].
The preparation phase of regeneration in urodeles shares many
similarities with wound healing in mammals [2,9,10]. Both
regeneration and wound healing are triggered by a trauma
(amputation or wounding) which is followed by the up-regulation
of many stress signals, inflammation and the formation of a blood
clot [5,9]. These events all occur within minutes after the trauma
and are followed shortly by the formation of a wound epithelium
[1,11–13]. The WE is usually formed within 2–6 hours post-
amputation in urodeles and between 12–48 hours post-wounding
in mammals [5,10,14]. If formation of the WE is prevented,
regeneration does not proceed and wound healing is retarded
significantly [1,10,11,15,16]. During the preparation phase,
following WE formation, there is extensive remodelling of the
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metalloproteinases (MMP) and tissue inhibitors of metallo-
proteinases as for wound healing in mammals [17–21].
Inhibitors of MMPs, such as GM6001, have been shown to
inhibit limb regeneration and to cause the appearance of a
scar-like layer of skin with collagen deposits on the stump of
amputated limbs [17].
As stated above, many cellular and physiological processes are
common to both axolotl limb regeneration and mammalian
wound healing. An important regulator of many of the
aforementioned events during wound healing is the transforming
growth factor-beta (TGF-b) signaling pathway. The TGF-b super-
family contains more than 30 structurally related growth and
differentiation factors including TGF-bs, BMPs, activins, inhibins,
and GDFs [22,23]. TGF-b1 is the most studied member of this
family for its roles in wound healing processes and immune
response in mammals [24–28]. TGF-b1 signals through two
transmembrane serine/threonine kinase receptors [TGF-b type I
receptor (also called ALK 5) and TGF-b type II receptor] that
phosphorylate the SMADs (SMAD 2 and 3) which activate target
genes in the nucleus. TGF-b1 has been shown to induce
proliferation of skin fibroblasts and to promote the migration of
fibroblasts and keratinocytes during wound healing [29–33]. The
participation of dermal fibroblasts in salamander limb regenera-
tion was first reported in 1954 and later confirmed by other groups
[1,34–36]. TGF-b1 also activates many target genes implicated in
wound healing and ECM production including connective tissue
growth factor (CTGF) and fibronectin, which were both shown to
be expressed in salamander regenerating tissues [15,28,37].
By combining PCR and cDNA library screening techniques, we
isolated the full length cDNA sequence of the axolotl TGF-b1. We
demonstrate that the TGF-b1 mRNA is up-regulated during the
preparation phase of limb regeneration and then down-regulated
during the redevelopment phase. These data are suggestive of
a role for TGF-b1 in the initiation and control of the regeneration
process. To address the requirement of TGF-b during regener-
ation, a specific inhibitor of TGF-b signaling, SB-431542, was
used [38]. The ease of administration of small pharmacological
inhibitors makes them powerful tools to address the role of specific
signaling/molecular pathways, such as the TGF-b pathway, in
complex in vivo physiological processes such as limb regeneration.
Recent publications on tissue regeneration present interesting
results using such inhibitors [17,39]. Many studies have used SB-
431542 to specifically block TGF-b signaling and TGF-b1
mediated effects [38,40–44]. Our results show that SB-431542
blocks limb regeneration in axolotls thus suggesting that TGF-
b signaling is essential for limb regeneration.
RESULTS
Identification of axolotl TGF-b1
Of the three mammalian TGF-b isoforms (i.e. TGF-b1, TGF-b2
and TGF-b3), TGF-b1 is recognized as the most important in
events related to wound healing processes and scar formation
[27,45,46]. By using a combination of cDNA library screening,
RT-PCR and RACE-PCR, a 1179 nucleotide cDNA sequence
corresponding to the axolotl TGF-b1 was isolated (GenBank
accession number EU147783). This fragment encodes a protein of
393 amino acids. As observed in other species, the sequence
contains a pro-domain and a TGF-b domain (Fig. 1). The pro-
domain of the axolotl protein aligns with the pro-domains of the
human and mouse proteins as 43% of the amino acid residues are
identical between the three sequences. The pro-domain, also
called the LAP (latency associated peptide, which is cleaved but
remains associated with the TGF-b domain until activation [47]),
is identified by a red box (Fig. 1). The mature TGF-b domain of
the axolotl protein (identified by a green box, Fig. 1) is well
conserved with 85% identity in amino acids compared to the
human and mouse domains. The axolotl TGF-b1 sequence was
also compared with Xenopus laevis TGF-b5. The axolotl TGF-b1
protein has 44% residue identity in the pro-domain and 80%
identity within the TGF-b domain of Xenopus laevis TGF-b5, which
is comparable with that of the human and mouse TGF-b1. In
addition, nine conserved cysteines which are considered essential
for TGF-b dimerization and transport were identified in the TGF-
b domain of the axolotl sequence (cysteines are identified in red,
Fig. 1) [48].
Expression of TGF-b1 mRNA during axolotl limb
regeneration
Whole-mount in situ hybridization was performed to verify if TGF-
b1 was expressed during the regeneration process. Figure 2
presents the spatio-temporal expression pattern of the TGF-b1
mRNA during limb regeneration. Expression of TGF-b1 was
detected as early as 6 hours post-amputation. Although the
expression at 6 hours post-amputation is hardly visible in whole-
mount samples (Fig. 2 A), it was detectable by Northern blot
analysis (Fig. 2 B). At 48 hours post-amputation, a strong up-
regulation of TGF-b1 mRNA was detected in whole-mounts (Fig. 2
A). A few days later, at the EB stage, TGF-b1 was still strongly
expressed and covered most of the blastema. The first 3 time
points of Figure 2 A are part of the preparation phase of
regeneration. During the redevelopment phase of limb regener-
ation, expression of TGF-b1 mRNA was very diffuse and barely
visible in the blastema from late bud to early differentiation stage,
in whole-mount samples (Fig. 2 A). Very week bands could be
detected on the Northern blots at these stages (Fig. 2 B). Each lane
on the Northern blot represents a pool of mRNA collected from
about 30 regenerating blastemas per stage, thus making this
technique more sensitive than whole-mount in situ hybridizations
which are individual blastema. Together, these results show that
TGF-b1 mRNA is expressed and regulated during limb re-
generation in the axolotl.
Presence of TGF-b receptors in axolotl cells
The presence of the TGF-b signaling machinery such as the type I,
II and III receptors were determined in our model using standard
biochemical approaches. First, affinity labeling using [
125I]-labeled
human TGF-b1 was performed on the AL-1 cell line, a fibroblast
cell line derived from the dermis of an axolotl limb [49]. This
technique involves covalent cross-linking of radioactively labeled
TGF-b1 to the receptors at the surface of the cell membrane [50].
After cell lysis, the three main receptors for TGF-b signaling:
TGF-b type I receptor, TGF-b type II receptor and TGF-b type
III receptor, also called betaglycan [51], were immuno-pre-
cipitated. Figure 3 A presents the results of the immuno-
precipitations. In lane 2, a band of 65 kDa corresponding to
TGF-b type I receptor can be observed. Subtracting the molecular
weight of the cross-linked monomeric TGF-b1 (12,5 kDa) results
in the expected size for TGF-b type I receptor, 53 kDa [52]. Two
other bands corresponding to unspecified proteins can also be seen
in lane 1. It was not possible to immuno-precipitate any labeled
proteins with the anti-TGF-b type II receptor antibody used (Fig. 3
A, lane 3). This could simply be due to non-immuno-reactivity of
the antibody with the axolotl receptor under these conditions. The
band in lane 4 corresponds to betaglycan, its high molecular
weight (200–350 kDa) and diffuse migration pattern are identical
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[53,54]. Having not succeeded in identifying TGF-b type II
receptor by immuno-precipitation, an alternative approach was
used to determine whether or not it was present. Western blot
analysis was performed on AL-1 cell protein extracts and a band of
the expected size (75 kDa) was observed (Fig. 3 B). In order to
confirm that this band was the type II receptor, the ability of UV
irradiation to reduce the expression of the specific band detected
on the Western blot was tested. A previous study had reported that
UV irradiation of human skin fibroblasts and mink lung epithelial
cells caused a decrease in TGF-b type II receptor protein
expression [55,56]. When axolotls cells were irradiated with high
levels of UVs (500 J/m
2), the expression of the band corresponding
to the TGF-b type II receptor protein was down-regulated, as
previously described [55,56] (Fig. 3 B). These results demonstrate
that the two main signaling TGF-b receptors (type I and II) and
one important accessory receptor (betaglycan) are present in limb
derived axolotl cells. Together with the identification of cDNAs
encoding SMAD proteins in the axolotl genome by the group of
Voss [57], our data suggest this species possesses the whole TGF-
b signal transduction machinery.
Activation of TGF-b1 target genes in axolotl cells
To verify that the TGF-b signaling cascade is functional in axolotl
cells, AL-1 cells were treated with human recombinant TGF-b1
protein and checked for target gene activation. The expression of
two TGF-b1 target genes was examined: plasminogen activator
inhibitor-1 (PAI-1), an immediate-early gene, and fibronectin, a late
response gene. Treatment of axolotl cells with 25 or 100 pM TGF-
b1 resulted in the up-regulation of PAI-1 expression 3 hours after
stimulation (Fig. 3 C). This correlates with the early expression
observed in other fibroblast cell lines [58]. The stimulation of axolotl
cells with TGF-b1 also resulted in a strong up-regulation of
fibronectin expression after 72 hours of treatment (Fig. 3 C), as
shown in a previous study in human dermal fibroblasts [59]. To
confirm our results, human keratinocytes HaCaT cells were used as
a positive control and checked for fibronectin induction after
72 hours of treatment with TGF-b1. As previously published,
HaCaT cells responded to TGF-b1 by an up-regulation of
fibronectin expression (Fig. 3 C) [60]. These results, combined with
the presence of the main TGF-b receptors in axolotl cells, confirm
that the TGF-b signaling machinery efficiently transduces signal to
the nucleus in axolotl cells. The ability of SB-431542 to block TGF-
Figure 1. Axolotl TGF-b1 protein sequence and domains. Alignment of axolotl (Ambystoma mexicanum) TGF-b1 amino acid sequence with TGF-b1
sequences of human (Homo sapiens), mouse (Mus musculus) and TGF-b5 of Xenopus (Xenopus laevis). In blue are residues of the axolotl sequence that
are conserved in the other three sequences. In red are the 9 conserved cysteine residues found in every TGF-b1 sequence. The red box identifies the
pro-domain of the protein. The green box identifies the mature TGF-b domain of the protein.
doi:10.1371/journal.pone.0001227.g001
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concentrationof25 mM,SB-431542efficientlyblockedtheTGF-b1-
mediated up-regulation of PAI-1 (Fig. 3 D).
Inhibition of axolotl limb regeneration by SB-431542
Many studies have shown that SB-431542 can inhibit TGF-
b signaling by binding to TGF-b type I receptor thus preventing
SMAD phosphorylation [38,40–43]. SB-431542 is highly specific as
it blocks TGF-b signaling, but not BMP or SMAD-independent
TGF-b signaling like p38 or ERK [38,40,41,43]. However, SB-
431542 can also block activin signaling but with a lower efficiency
thanTGF-b signaling as reported by theIC50for ALK4 (activin type
Ir e c e p t o r ,I C 50=140nM) and ALK5 (TGF-b type I receptor,
IC50=94nM) [38,41]. To investigate whether TGF-b signaling is
required for limb regeneration, regenerating axolotls were treated
with SB-431542. Results presented in Figure 4 show that limb
regeneration was completely blocked in axolotls treated with SB-
431542 at a final concentration of 25 mM (Fig. 4 A). This
concentration represents the lower spectrum of concentrations
reported inin vivo studies using this inhibitor[61–63]. At 25 mM, SB-
431542 was not toxic for the animals as they grew and fed normally.
In control animals, DMSO treatment did not prevent limb
regeneration (Fig. 4 A). Treatment of axolotls with SB-431542 at
lower concentrations provided incomplete blocking of regeneration
(data not shown). When axolotls were treated with SB-431542, from
the moment of amputation until control animals had regenerated
(30 days), regeneration was completely blocked. In these animals,
wound epithelium formation was observed but blastema formation
was absent (Fig. 4 A). Animals were also treated with SB-431542
starting at early bud (EB) stage until the end of regeneration. When
treated at EB, the blastema increased in size for a few days until it
reached a final shape/size comparable to a late bud blastema,
stopped growing and never regenerated (Fig. 4 A). The effects of SB-
431542 treatments on regenerating tissue were also tested to
determine whether the observed inhibition was reversible or
permanent. Figure 4 B shows that limbs treated daily with SB-
431542 for 7 or 14 days post-amputation did not reinitiate the
regeneration process when the treatment was stopped. Animals
treated with SB-431542 for the first 48 hours post-amputation
regenerated their limbs with only a slight delay compared to controls
(data not shown).
Figure 2. Expression of TGF-b1 during axolotl limb regeneration. A) Expression of TGF-b1 determined by whole-mount in situ hybridization in
axolotl forelimbs. Limbs were amputated distally through radius/ulna. Samples were fixed at various times after amputation: 6 hours (6 h), 48 hours
(48 h), early bud (EB), late bud (LB) and early differentiation (ED) stage. TGF-b1 expression is found as a dark purple precipitate. The 3 stages on the
upper row are part of the preparation phase of limb regeneration. The 2 stages on the lower row are part of the redevelopment phase of limb
regeneration. B) Northern blot showing expression of TGF-b1 at various stages of forelimb regeneration. TGF-b1 was detected as a 3.4 Kb transcript.
RNA was extracted from regenerating blastemas at various times after amputation: 6 hours (6 h), 24 hours (24 h), 48 hours (48 h), early bud (EB), late
bud (LB), palette (PAL) and early differentiation (ED) stage. T=0: RNA was extracted from an unamputated mature limb. The dotted line marks
a distinction between regeneration stages included in the preparation phase and those included in the redevelopment phase of regeneration.
doi:10.1371/journal.pone.0001227.g002
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regeneration
Figure 5 shows a time course of regenerating limbs treated with
SB-431542 or DMSO (control). Although the wound at the tip of
the stump is still open on both control and SB-431542 treated
limbs, after forty-five minutes following amputation (Fig. 5 A and
B), a slight delay in wound closure can be observed in SB-431542
treated limbs. Two hours after amputation, the WE had
completely closed the wound in control limbs (Fig. 5 C) which is
in accordance with results reported previously by Carlson et al.
[14]. In SB-431542 treated limbs, the WE had not completely
closed the wound 2 h post-amputation (Fig. 5 D). However, at 6 h
post-amputation, the WE covered the tip of the limbs in both
control and SB-431542 treated animals (Fig. 5 E and F). At 48 h
post-amputation, streams of cells migrating between the end of the
bone and the WE can be seen in controls but not in SB-431542
treated limbs (Fig. 5 G and H). At 72 h post-amputation, cells are
still migrating toward the WE in control limbs (Fig. 5 I). Those
cells will accumulate to form the regeneration blastema [1]. In
limbs treated with SB-431542, no cellular accumulation at the end
of the limb in any of the samples analyzed at 72 h could be
observed (Fig. 5 J). At 7 days post-amputation, control limbs have
reached early/medium bud stage with a prominent blastema
(Fig. 5 K). Cells that have migrated and proliferated now occupy
a large space between the tip of the bone and the WE. At this
Figure 3. Detection of TGF-b receptors and target genes in axolotl cells. A) Presence of TGF-b receptors after affinity labeling of axolotl AL-1 cell
line with [
125I]-TGF-b1. Lane 1: (NIP): Cell lysates were not immuno-precipitated. A band corresponding to TGF-b RI around 65 kDa can be observed.
Lane 2: Proteins were immuno-precipitated with anti-TGF-b RI antibody. A band corresponding to TGF-b RI at 65 kDa is also observed in this lane.
Two other bands were observed in this lane. These bands correspond to unspecified proteins that co-immuno-precipitated with TGF-b RI. Lane 3:
Proteins were immuno-precipitated with anti-TGF-b RII antibody. No band was detected. Lane 4: Proteins were immuno-precipitated with anti-TGF-
b RIII/betaglycan antibody. A diffuse band of high molecular weight (200–350 kDa) corresponding to TGF-b RIII/betaglycan was detected. B) Western
blot experiment showing the presence of TGF-b RII in axolotl AL-1 cells. Ctl lane represents TGF-b RII protein expression in control axolotl cells not
exposed to U.V. light. Other lanes present diminished expression of TGF-b RII in axolotl cells exposed to 500 J/m
2 U.V. and collected after 6 h, 12 h
and 24 h. Expression of TGF-b RII in control cells at 6 h, 12 h and 24 h was stable (data not shown). Loading control (tubulin) confirms equal loading
of protein samples. C) RT-PCR results of PAI-1 and fibronectin expression in AL-1 cells after stimulation with human recombinant TGF-b1. Strong up-
regulation of both genes was observed after stimulating cells with 25 or 100 pM TGF-b1. Up-regulation was detected 3 h and 72 h after stimulation
for PAI-1 and fibronectin respectively. The human keratinocyte cell line (HaCaT) was used as a positive control for fibronectin induction at 72 h. Ctl:
control cells treated only with 4 mM HCl, 0,1% bovine serum albumin buffer (TGF-b1 carrier solution) . L: 100 base-pair DNA ladder with the most
intense band at 600 bp. GAPDH was used as a control gene. D) RT-PCR results showing PAI-1 expression in AL-1 cells after stimulation with DMSO,
human recombinant TGF-b1 and human recombinant TGF-b1 in the presence of SB-431542. The TGF-b1 stimulated expression of PAI-1 was
significantly inhibited by SB-431542.
doi:10.1371/journal.pone.0001227.g003
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remodeled as previously reported by Tank et al. [64] (Fig. 5 K). In
comparison, limbs treated with SB-431542 still show no sign of
blastema formation and the tip of the bone did not show any sign
of being remodeled as in control limbs at this time point (Fig. 5 L).
Cell proliferation analysis in SB-431542 treated
limbs
Knowing that TGF-b signaling is important in regulating cell
growth, the effect of SB-431542 treatment on cellular proliferation
in axolotl limbs was verified. To measure this effect, a BrdU
labeling experiment, consisting in injecting BrdU solution intra-
peritoneally in control and SB-431542 treated axolotls, was
performed 7 days post-amputation. Results presented in Figure 6
show BrdU labeled cells in the regenerating blastema of a control
animal (Fig. 6 A) and in the limb of an SB-431542 treated animal
(Fig. 6 B). In the control limb, many cells in the blastema are in
a proliferative state as determined by the presence of BrdU labeled
cells (Fig. 6 A). In comparison, a very small number of cells,
excluding a few skin cells, are labeled for BrdU in SB-431542
treated limbs (Fig. 6 B). The graph presented in Figure 6 C shows
a significant difference in the percentage of BrdU positive cells
between the blastema region in controls and the tip of the limb in
Figure 4. Inhibition of limb regeneration by SB-431542. A) Morphology of axolotl regenerating forelimbs treated with SB-431542. Top row:
morphology of a regenerating control limb treated with DMSO. All limbs were distally amputated on the same day. Limbs were photographed when
control limbs reached each of the stages indicated on top: early bud (EB), late bud (LB), early differentiation (ED). Complete: regeneration of control
limb ended after 30 days. Middle row: morphology of an axolotl limb treated with 25 mM SB-431542 from the time of amputation until the control
had regenerated (30 days). Complete inhibition of regeneration and absence of blastema formation were observed in these limbs. Bottom row:
morphology of an axolotl limb treated with 25 mM SB-431542 from early bud stage until the control had regenerated. Growth of the blastema was
observed in these limbs until it resembled a late bud blastema. B) Inhibition of regeneration with SB-431542 cannot be rescued after 7 or 14 days of
treatment. In this panel, limbs were treated with DMSO or SB-431542 from the moment of amputation for the first 7 or 14 days only. Results show
that limbs treated with SB-431542 for the first 7 or 14 days after amputation do not regenerate even if treatment was stopped. Control limbs treated
for 7 and 14 days with DMSO regenerated normally.
doi:10.1371/journal.pone.0001227.g004
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blocks cellular proliferation in axolotls and suggest that TGF-
b signaling controls cellular proliferation during limb regeneration.
Measurement of TGF-b1 target genes expression in
SB-431542 treated limbs
After examining the effects of SB-431542 on cellular growth in vivo,
the ability of this inhibitor to block the expression of two TGF-b1
target genes, fibronectin and Runx 2, during limb regeneration
was tested. Figure 7 shows RT-PCR amplification of TGF-b1
target genes in control and SB-431542 treated limbs. Strong
fibronectin and Runx 2 expressions were observed in control limbs
5 days after amputation (Fig. 7 A), which are consistent with the
time-frame of studies looking at the expression of these genes in
axolotl regenerating limbs [15,65]. In contrast, both fibronectin
and Runx 2 were significantly down-regulated in SB-431542
treated limbs (Fig. 7 A). GAPDH expression was not affected by
SB-431542, as all other control genes tested (cyclophilin D, beta-
actin, EF1-a, data not shown). Densitometric analysis of the PCR
bands in Figure 7 A shows that fibronectin expression in control
limbs was about 3 times higher and Runx 2 expression was about
15 times higher than in SB-431542 treated limbs (Fig. 7 B). These
results demonstrate that SB-431542 treatment affects the expres-
sion of known TGF-b1 target genes, fibronectin and Runx 2, by
down-regulating their expression in regenerating limbs.
DISCUSSION
TGF-b1 is a multi-functional cytokine implicated in many aspects
of mammalian wound healing and scar tissue formation processes
[5,27,66–69]. Interestingly, urodele amphibians such as the axolotl
can regenerate many parts of their body following amputation and
never seem to form scar-tissue [1]. Given that mammalian wound
healing and axolotl limb regeneration share many similarities in
their initial phases [2,5,10], we examined the requirement of
TGF-b signaling and TGF-b1 expression during axolotl limb
regeneration.
Isolation of the axolotl TGF-b1 cDNA and translation of the
protein sequence through NCBI BLAST (http://www.ncbi.nlm.
nih.gov/BLAST/) indicated that the sequence has high homology
with mammalian sequences for TGF-b1 [i.e. very low (E) values
Figure 5. Histological analysis of regenerating limbs treated with SB-431542. Control limbs were treated with DMSO from time of amputation and
fixed A) 45 minutes, C) 2 hours, E) 6 hours, G) 48 hours, I) 72 hours and K) 7 days after amputation. Samples treated with 25 mM SB-431542 from time
of amputation were fixed at B) 45 minutes, D) 2 hours, F) 6 hours, H) 48 hours, J) 72 hours and L) 7 days after amputation. Masson’s trichrome
staining method was used to stain cell cytoplasm in red, collagen in blue and nuclei in black. Note the delayed closure of the wound epithelium in SB-
431542 treated limbs at 45 minutes and 2 hours post-amputation. Also note that there is no blastema formation or accumulation of cells between
the tip of the bone and the wound epithelium in SB-431542 treated limbs.
doi:10.1371/journal.pone.0001227.g005
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a greater similarity), the lowest (E) being 7e
2112 and corresponding
to Equus caballus (horse) TGF-b1]. These values confirmed that the
isolated sequence corresponded to the axolotl TGF-b1. The
sequence also has high homology with the TGF-b5 sequence of
Xenopus laevis, an anuran amphibian [(E) value of 1e
2103]. A TGF-b1
orthologue has never been isolated in Xenopus laevis for which over
650 000 EST are available (data from GenBank). However,
phylogenetic analyses suggest that the Xenopus TGF-b5 is actually
the orthologue of the mammalians TGF-b1[ 2 3 ] .
A rapid up-regulation of TGF-b1 expression was observed
following limb amputation and was maintained at a high level
throughout the preparation phase of limb regeneration. As
mentioned above, TGF-b1 is a key regulator of wound epithelium
formation, inflammation, blood clot formation, and ECM remodel-
ing in mammalian wound healing processes [5,26,27,32,33]. Axolotl
Figure 6. Inhibition of cellular proliferation in regenerating limbs treated with SB-431542. A) Control regenerating limb treated with DMSO and
assessed for BrdU incorporation at 7 days post-amputation (medium bud stage). Red arrowhead marks a cell positive for BrdU. Note the
accumulation of BrdU-positive cells in the regenerating blastema. Cells positive for BrdU are also found (at a lower frequency) in the epidermis of the
non-regenerating part of the limb. B) SB-431542 treated limb assessed for BrdU incorporation 7 days post-amputation. No accumulation of BrdU-
positive cells at the tip of the limb is observed. Only a few positive cells are found mostly in the epidermis of the limb (red arrowhead). Dotted lines in
panels A and B represent the level of amputation. C) Graph comparing percentage of BrdU-positive cells in the regenerating blastema of control
limbs (n=3 animals) and in SB-431542 treated limbs (n=3 animals). A statistically significant difference in the percentage of BrdU positive cells
between control (38%66.2%) and SB-431542 treated limbs (7%62.1%) was observed (*** p,0.001).
doi:10.1371/journal.pone.0001227.g006
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wound healing and most of them are essential for regeneration to
take place [2,8]. Fibroblasts participate in both processes: in
mammals they invade granulation tissue and mediate wound
contraction; in the axolotl they dedifferentiate and provide one of
the main sources of blastema cells for the regenerating limb
[2,5,35,36]. At the early bud stage, when blastema cells are
proliferating rapidly, a strong expression of TGF-b1 is present in
the blastema. It is possible that, in the preparation phase of
regeneration, TGF-b1 could be expressed to promote detachment
and migration of mesenchymal cells towards the blastema. Martin et
al. suggested that TGF-b1 acts in a similar way to promote
mesenchymal cell proliferation during mammalian embryonic
wound healing [70]. Mammalian embryos can heal their skin
wounds perfectly following injury [71]. In E11.5 mouse embryos,
TGF-b1 is rapidly expressed at the site of injury in response to
wounding. TGF-b1 expression reaches a peak at 3–6 hours after
wounding and is quickly down-regulated 18 hours post-wounding,
just before the wound has fully closed/healed [70]. Moreover, just as
in the axolotl, mammalian embryos present a diminished immune
response following injury [5,71,72]. In mammalian adults, TGF-b1
rapidly promotes inflammation and recruits immune cells like
macrophages, leukocytes and lymphocytes, when released at the
wound site [45,66,73,74]. Because of its pro-inflammatory effects,
prolonging TGF-b1 expression at the wound site does not benefit
wound healing [73]. However, it has been reported that axolotls are
immuno-tolerant and exhibit a weak immune response following
grafts or injuries [9,75,76]. In fact, very low levels of inflammatory
cells are present at the wound site of amputated limbs [77]. It is
believed that the reduced immune response following limb
amputation could be linked to the regenerative capacity of
salamanders [9]. The data presented in this paper demonstrate that
TGF-b1 is expressed during the preparation phase of limb
regeneration, when cells of mesenchymal origin dedifferentiate,
migrate and divide rapidly to form the regeneration blastema.
In order to functionally analyze the role of TGF-b signaling
during axolotl limb regeneration, we treated regenerating axolotls
with the pharmacological inhibitor SB-431542. Numerous studies
have reported the ability of SB-431542 to inhibit TGF-b signaling
by blocking the ALK5 mediated phosphorylation of Smad2/
Smad3 in various cell lines [38,40–44,78,79]. Our data demon-
strate that SB-431542 blocks axolotl limb regeneration and thus
provides the first line of evidence that TGF-b signaling is essential
for this process to take place. Histological analysis of SB-431542
treated limbs suggests that TGF-b signaling affects cellular
migration during regeneration, since wound healing is delayed
Figure 7. Inhibition of TGF-b1 target genes expression in regenerating limbs treated with SB-431542. A) RT-PCR showing expression of fibronectin
and Runx 2 in axolotl regenerating forelimbs. RT-PCR reactions were performed on at least 4 separate RNA samples extracted from pools of 6
blastemas of animals treated with DMSO or SB-431542. Fibronectin and Runx 2 were strongly expressed in control limbs and significantly down-
regulated in limbs treated with SB-431542. GAPDH was used as a control. B) Graph representing the relative value of fibronectin/GAPDH and Runx 2/
GAPDH expression in control and SB-431542 treated limbs. Fibronectin and Runx 2 relative expression in control limbs were fixed to 160.37 and
160.09 respectively. The relative expression values in SB-431542 treated limbs were 0.2960.23 with a p,0.05 (*) for fibronectin and 0.0760.01 with
ap ,0.001 (***) for Runx 2.
doi:10.1371/journal.pone.0001227.g007
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a key player in regulating this process as it is a potent chemo-
attractant of fibroblasts during mammalian wound healing
[30,31]. TGF-b signaling also promotes cell growth in regenerat-
ing limbs as demonstrated by the very low incorporation of BrdU
in SB-431542 treated limbs. The inhibitory effects of SB-431542
on limb regeneration could also in part be due to the down-
regulation of fibronectin or Runx 2 expression. Fibronectin,
a component of the extra-cellular matrix which is a target gene of
TGF-b1, has been suggested to play an important role in epithelio-
mesenchymal interactions during axolotl limb regeneration [15]. If
those interactions do not take place or are reduced, limb
regeneration could be inhibited [8,16]. Runx 2, also named
Cbfa-1, is a transcription factor that regulates mesenchymal
condensation, chondrocyte hypertrophy and osteoblast differenti-
ation [80,81]. It is a target gene of TGF-b1 and was shown to be
expressed in regenerating axolotl limbs [65,82]. Inhibition of
TGF-b signaling with SB-431542 in axolotl limbs resulted in
a down-regulation of Runx 2 mRNA as previously shown in
mammalian cells, [83]. Results also show that, beyond a certain
point, the effect of SB-431542 treatment on regenerating limbs
becomes irreversible. 48 hours of treatment with SB-431542 only
slightly delayed limb regeneration (data not shown), but inhibition
became irreversible when treatment was sustained for 7 days or
more. The reasons why 7 days of treatment become irreversible
are not clear at the moment. Histological analysis does not show
any sign of scar tissue appearance like those reported by
Odelberg’s group while blocking MMPs [17]. It could be that
the WE lost its permissive abilities due to the lack of mesenchymal
cell accumulation to form a blastema. The present results obtained
with SB-431542 imply that TGF-b signaling controls the
formation and growth of the regeneration blastema. In mammals,
wound healing often results in scar formation which is regulated by
TGF-b signaling [27,69,84]. Many studies have reported re-
duction of scarring in mammals when wounds are treated with
chemical inhibitors or specific antibodies aimed at TGF-b isoforms
(particularly TGF-b1) during the healing process [66–68,85–89].
The situation seems to be very different in the axolotl as blocking
of TGF-b signaling prevented limb regeneration. Our data show
that TGF-b signaling is essential for the regeneration of the axolotl
limb, a complex tri-dimensional structure, and suggest a new role
for TGF-b signaling in regenerative biology.
Recently, Jazwinska et al. used SB-431542 to examine zebrafish
fin regeneration and reported that SB-431542 inhibited blastema
formation in amputated fins, allowing only WE formation [90].
These results are consistent with our data in axolotls. In their
paper, Jazwinska et al. demonstrate that SB-431542 blocked
cellular proliferation in treated fins, as detected by a reduction of
BrdU labeling which we also observe in axolotl limbs. Moreover,
in both models, treatment of regenerating appendages at mid-
stages of regeneration (4 days post-amputation in zebrafish and
early bud stage in the axolotl) completely blocked the process,
suggesting that TGF-b/activin signaling is essential to maintain
the proliferation of blastema cells. In the present paper, whole-
mount in situ hybridization and Northern blot results demonstrate
that TGF-b1 is regulated during axolotl limb regeneration.
Although Jazwinska et al. show that activin-bA (Act-bA) is the
only TGF-b family member strongly regulated during zebrafish fin
regeneration, their data also indicate that TGF-b1 and TGF-b3
are expressed at significant levels during the regeneration process
[90]. Interestingly, their results indicate that TGF-b1 expression is
between 10–40 times higher than that of Act-bA in uninjured fins
and at 6h and 24h post-amputation. Considering the fact that SB-
431542 has a higher affinity for the TGF-b type I receptor ALK-5
(IC50=94nM) than for the activin type I receptor ALK-4
(IC50=140 nM) [38,41], the inhibition of zebrafish fin regener-
ation observed by Jazwinska et al. [90] could in part be due to the
inhibition of TGF-b signaling.
In summary, we show that TGF-b1, a key player in mammalian
wound healing, is rapidly up-regulated following amputation and
strongly expressed during the preparation phase of axolotl limb
regeneration. By blocking limb regeneration with SB-431542,
a potent inhibitor of TGF-b type I receptor (ALK-5), we show that
TGF-b signaling is essential for limb regeneration. The cellular
mechanism by which TGF-b may regulate axolotl limb re-
generation is an interesting area for future investigations and will
help in understanding the differences and similarities between
mammalian wound healing and axolotl tissue regeneration.
MATERIALS AND METHODS
Animal maintenance and treatments
Axolotl (Ambystoma mexicanum) embryos and larvae were purchased
from the Ambystoma Genetic Stock Center (Lexington, KY).
Animals were maintained as previously published by Le ´vesque et
al. [91]. SB-431542 (Tocris Bioscience, Ellisville, MO) was
purchased from Cedarlane Laboratories (Burlington, ON) and
diluted to a stock concentration of 10mM in DMSO. After limb
amputation, animals (2–5 cm) were kept in 5 mL of 20%
Holtfreter’s solution containing SB-431542 at a final concentration
of 25 mM or DMSO for controls. The Holtfreter’s solution
containing either SB-431542 or DMSO was changed daily. A
minimum of 3 animals were treated for each condition. Animal
care and experiments were done in accordance with the Universite ´
de Montre ´al animal care committee’s guidelines.
Cloning of axolotl TGF-b1 cDNA
Total RNA was extracted from axolotl larvae and cells using
Trizol reagent (Invitrogen, Carlsbad, CA). Reverse transcription
reactions were done at 50uC using Superscript II reverse
transcriptase (Invitrogen). A 495 base pair cDNA fragment
encoding the axolotl TGF-b1 was first isolated using RT-PCR
from larvae total RNA with primers DFTGFB1 (degenerate
forward TGF-b1) and DRTGFB1 (degenerate reverse TGF-b1)
obtained from Sigma Genosys (Oakville, ON.). This fragment was
then used to screen a pre-made axolotl cDNA library (cat. #
937670, Stratagene, La Jolla, CA). This screening resulted in the
isolation of a larger fragment corresponding to the axolotl TGF-
b1. To complete the sequence, 59 RACE-PCR (Rapid Amplifi-
cation of cDNA Ends) was done using the BD Smart-RACE kit
(cat. # 634914, BD Biosciences, Mississauga, ON.). For this
method, axolotl gene-specific primers were designed: ATGFR210
(Axolotl TGF-b1 reverse 210) and ATGFR367 (Axolotl TGF-b1
reverse 367). RNA from limb medium bud blastemas was used to
synthesize the first strand for the 59 RACE reaction. The RACE
and PCRs were performed following the manufacturer’s in-
struction. A PCR was performed to amplify the axolotl TGF-b1
complete cDNA using the following primer pairs: ATB1F1067
with ATB1R2419 which gave a fragment of 1352 base pairs, and
ATB1F1098 with ATB1R2368 which gave a fragment of 1270
base pairs. These fragments were cloned into the PCR II-TOPO
vector (Invitrogen). Following sequencing of each fragment at the
Genome Que ´bec sequencing Center a BLAST search was per-
formed in GenBank (http://www.ncbi.nlm.nih.gov/BLAST/).
The axolotl TGF-b1 protein structure domains were also obtained
from GenBank (http://www.ncbi.nlm.nih.gov/Structure/cdd/
cdd.shtml). The alignment of TGF-b1 protein sequences was
compiled with the Lasergene program (DNAStar, Madison, WI)
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(accession number P01137), mouse TGF-b1 (accession number
NP_035707) and Xenopus laevis TGF-b5 (accession number
AAB64441) were aligned with the axolotl TGF-b1 sequence
(accession number EU147783).
Whole-mount in situ hybridization
Whole-mount in situ hybridization was performed as described by
Gardiner et al. [7] with a few modifications. Digoxygenin labeled
antisense RNA probe for TGF-b1 was synthesized using T3 RNA
polymerase (Promega, Madison, WI) and DIG RNA labeling mix
(Roche Diagnostics, Laval, QC). The PCR-Script Amp SK+
vector (Stratagene) containing the 495 bp TGF-b1f r a g m e n tw a s
linearized with EcoR1 and used as template for probe synthesis. For
tissue permeabilization, limbs were incubated with 30mg/ml
proteinase K for 30–60 minutes on ice and then at 37uCf o r4 5 –
60 minutes with the time adjusted for blastema size. Prehybridiza-
tion and hybridization (72 hours) temperature was 62.5uC. For
alkaline-phosphatase reaction, BM purple (Roche) was used as the
enzyme substrate for the colorimetric reaction. No signal was
detected at any stage when the sense probe was used for in situ
hybridization (data not shown). A minimum of 3 samples, for each
regeneration stage, was used for Whole-mount in situ hybridization.
Northern blots
Limb regeneration stages were determined as described by Tank
[64] and Iten [92]. Total RNA was extracted from blastemas at
each stage using Trizol. T=0 corresponds to RNA extracted from
mature limb tissue. Messenger RNA was extracted using GenElute
mRNA Miniprep kit (Sigma-Aldrich, St-Louis MO). 20 mg of total
RNA or 5 mg of mRNA were loaded per lane on a 1% agarose-
6.9% formaldehyde gel. RNA was transferred from the gel to
a nylon membrane (Pall, USA) by capillary transfer. A cDNA
probe coding for the axolotl TGF-b1 was amplified from the PCR-
Script amp SK+ vector. The membranes were hybridized with this
cDNA probe labeled with [a-
32P]deoxy-CTP by the random
hexamer method as in Roy et al.[93]. Northern blots were repeated
3 times with different RNA samples for each regeneration stage.
Affinity labeling of axolotl cells
Axolotl cells (AL-1 cell line) grown in culture were maintained at
a constant temperature of 26uC without CO2 in 60% Leibovitz’s L-
15 medium with 2mM L-glutamine, 100 units/mL penicillin-
streptomycin, 16 insulin-transferrin-selenium (diluted from 1006
stock solution, Invitrogen) and 5% fetal bovine serum (FBS; Gibco,
Invitrogen). Axolotl cells in culture were labeled with [
125I]-TGF-b1
human recombinant protein and immuno-precipitations of TGF-
b receptors were performed, as described previously [50,60].
Immuno-precipitations of TGF-b receptors were done using the
following antibodies: anti-TGF-b RI (V-22) (Santa Cruz bio-
technology, CA), anti-TGF-b RII (C-16) (Santa Cruz biotechnolo-
gy),anti-betaglycanGet-1asdescribedinPieketal.[52].SDS-PAGE
was performed under reducing conditions using b-mercaptoethanol.
Affinity labeling of axolotl cells was repeated two times.
UV irradiation of axolotl cells and Western blot
analysis
Axolotl AL-1 cells were irradiated with ultra-violet (UV) light
(500 J/m
2) and were harvested 6, 12 and 24 hours post-
irradiation. Total proteins were extracted by sonicating cells in
sodium dodecyl sulfate (SDS) sample buffer and heated in boiling
water 5 minutes before electrophoresis on 12% polyacrylamide-
SDS gels according to the method of Laemmli [94]. Fifty
micrograms of proteins were loaded per lane. The proteins were
transferred electrophoretically onto PVDF membranes (Immobi-
lon-P, Millipore, Bedford, MA). For Western blotting, we used
a 1:200 dilution of an anti-TGF-b RII (C-16) #sc-220 antibody
(Santa Cruz biotechnology). Immuno-detection of primary
antibody was visualized using the ECL Western blotting kit
according to the manufacturer’s directions (GE Healthcare,
Buckinghamshire, UK). Experiments were repeated at least 3
times with different protein samples for each experiment.
Treatments of axolotl cell line with TGF-b1 protein
and SB-431542
Human recombinant TGF-b1 protein was used to treat AL-1 cells
at a final concentration of 25 or 100 pM. Cells were serum starved
and kept in 60.0% Leibovitz’s L-15 medium for 48 h prior to
adding TGF-b1. Total RNA was collected (using Trizol reagent)
from AL-1 cells treated with TGF-b1 after 3 and 72 hours.
HaCaT human keratinocyte cell line was grown in DMEM
medium with 2mM L-glutamine, 100 units/mL penicillin-
streptomycin, and 10% FBS and used as control. SB-431542
was added 30 minutes before TGF-b1 treatment. Each experi-
ment was performed in triplicates.
RT-PCR
RT-PCR reactions were done using RNA collected from axolotl
cells in culture or regenerating limb blastemas. 30 cycles of PCR
amplification were done for each gene. Primers used to amplify
each genes are as follows: axolotl plasminogen activator inhibitor 1
(PAI-1) APAI1F183 and APAI1R706, axolotl fibronectin AFNF31
and AFNR411, axolotl Runx 2 ARUNX2F66 and ARUNXR295,
human fibronectin HFNF87 and HFNR335, axolotl glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) AGDHF90 and
AGDHR391 and human glyceraldehyde-3-phosphate dehydroge-
nase HGAPDH 59 and HGAPDH 39 (See Table 1 for primer
sequences). To measure the effect of SB-431542 on TGF-b1 target
genes expression, animals were treated for 5 days following
amputation with DMSO (controls) or SB-431542. RNA was
extracted from blastemas or the tip of the limbs of comparable size
for SB-431542 treated animals and RT-PCR was performed. Each
sample comes from a reverse transcription reaction made with 6
blastemas from control or SB-431542 treated limbs. Student’s T
test was performed to confirm statistical significance of fibronectin
and Runx 2 expression in control versus SB-431542 treated limbs
(4 samples per condition).
Histology
Following treatments with SB-431542 or DMSO, axolotls were
fixed overnight in Bouin’s fixative solution and then rinsed
thoroughly with 70% alcohol. Limbs were embedded in paraffin
and cut to 10 mm sections. Slides were deparaffinized through 3
baths of toluene for 5 minutes each. Slides were then rehydrated in
a graded series of 100%, 90%, 70% and 50% alcohol and then
distilled water for 5 minutes each. For histology, Masson’s
trichrome staining method was used to stain cell cytoplasm in
red, nuclei in black and collagen in blue [95]. A minimum of 3
samples were stained for each time-point.
BrdU incorporation assay
Regenerating control and SB-431542 treated axolotls were
injected intra-peritoneally, 7 days after amputation, with 10mL
of BrdU stock solution using a ratio of 1–2mL/100 g of body
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care, # RPN201). Animals were fixed 12 hours after injection in
4% paraformaldehyde in 0.76PBS for 24 hours at 4uC. Samples
were paraffin embedded, deparaffinized and rehydrated as for
histology. For immuno-histochemistry, slides were washed
4615 minutes in PBST (16 PBS with 0,1% Tween 20). They
were incubated with 0.8% Pepsin in 0,2N HCl for 10 minutes at
37uC to promote denaturation of DNA. Slides are then washed
3610 minutes in PBST, and incubated in a blocking solution (2%
bovine serum albumin, 1% DMSO, 10% sheep serum and 0,1%
Triton X-100) at room temperature for one hour. Slides were then
incubated overnight at 4uC with an anti-BrdU mouse monoclonal
antibody (BrdU Ab-3, Labvision/Neomarkers, Fremont, CA.)
diluted 1:50 in blocking solution. PBST washes (4615 minutes)
were done before incubating with an anti-mouse secondary
antibody coupled to horseradish peroxidase, dilution 1:250, for
2 hours at room temperature (GE Healthcare). Slides were washed
again 4615 minutes in PBST before being incubated in DAB
(Zymed, Invitrogen) for signal detection. Slides were counter-
stained with methyl green for 6 minutes (Dako, Mississauga, ON)
before being serially dehydrated 262 minutes each in 90% EtOH,
100% EtOH and 100% Xylene. Slides were mounted with
Permount (Fisher scientific, Ottawa, ON). Immunohistochemical
detection for BrdU incorporation was done on three different
samples. Student’s T test was performed to confirm statistical
significance of BrdU incorporation in control versus SB-431542
treated limbs (3 samples per condition).
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